Patents by Inventor Ralph Tripp

Ralph Tripp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10626379
    Abstract: The present invention relates to methods of replicating viruses in vitro. In particular, the invention relates to a genetically modified population of cells, and/or a population of cells treated with an exogenous compound, wherein the cells are capable of producing more virus than cells lacking the genetic modification and/or lacking treatment with the exogenous compound. The invention also relates to methods of producing populations of such cells, as well as the use of the viruses obtained to prepare vaccine compositions.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: April 21, 2020
    Assignees: Commonwealth Scientific and Industrial Research Organisation, University of Georgia Research Foundation, Inc.
    Inventors: Andrew Bean, John William Lowenthal, Luis Fernando Malaver-Ortega, Ralph A. Tripp
  • Publication number: 20200010830
    Abstract: Disclosed are compositions and methods for increasing virus production.
    Type: Application
    Filed: March 8, 2018
    Publication date: January 9, 2020
    Inventor: Ralph A Tripp
  • Publication number: 20190322989
    Abstract: The present invention relates to methods of replicating viruses in vitro. In particular, the invention relates to a genetically modified population of cells, and/or a population of cells treated with an exogenous compound, wherein the cells are capable of producing more virus than cells lacking the genetic modification and/or lacking treatment with the exogenous compound. The invention also relates to methods of producing populations of such cells, as well as the use of the viruses obtained to prepare vaccine compositions.
    Type: Application
    Filed: January 25, 2019
    Publication date: October 24, 2019
    Inventors: Andrew Bean, John William Lowenthal, Luis Fernando Malaver-Ortega, Ralph A. Tripp
  • Publication number: 20190203186
    Abstract: The present invention relates to modified avian eggs which can be used to produce increased levels of virus. The present invention also relates to methods of producing viruses in avian eggs of the invention, as well as the use of the viruses obtained to prepare vaccine compositions.
    Type: Application
    Filed: January 25, 2019
    Publication date: July 4, 2019
    Inventors: Andrew Bean, John William Lowenthal, Luis Fernando Malaver-Ortega, Ralph A. Tripp
  • Publication number: 20180340153
    Abstract: The present invention relates to methods of replicating viruses in vitro. In particular, the invention relates to a genetically modified population of cells, and/or a population of cells treated with an exogenous compound, wherein the cells are capable of producing more virus than cells lacking the genetic modification and/or lacking treatment with the exogenous compound. The invention also relates to methods of producing populations of such cells, as well as the use of the viruses obtained to prepare vaccine compositions.
    Type: Application
    Filed: November 23, 2016
    Publication date: November 29, 2018
    Inventors: Andrew Bean, John William Lowenthal, Luis Fernando Malaver-Ortega, Ralph A. Tripp
  • Publication number: 20180340154
    Abstract: The present invention relates to modified avian eggs which can be used to produce increased levels of virus. The present invention also relates to methods of producing viruses in avian eggs of the invention, as well as the use of the viruses obtained to prepare vaccine compositions.
    Type: Application
    Filed: November 23, 2016
    Publication date: November 29, 2018
    Inventors: Andrew Bean, John William Lowenthal, Luis Fernando Malaver-Ortega, Ralph A. Tripp
  • Patent number: 10137188
    Abstract: Provided herein are engineered cell lines. In some embodiments, cells of an engineered cell line have altered expression of a gene and/or altered expression of an miRNA, wherein the altered expression results in increased or decreased production of a virus. The virus is a picornavirus, such as a poliovirus or Enterovirus 71. Also provided herein are methods for using the engineered cells to produce virus, and methods for treating a subject having or at risk of having a viral infection.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: November 27, 2018
    Assignees: University of Georgia Research Foundation, Inc., The United States of America, as represented by the Secretary, Dept. of Health and Human Services, Thermo Fisher Scientific, Inc.
    Inventors: Jon Michael Karpilow, Mark Steven Oberste, Ralph A. Tripp, Stephen M. Tompkins
  • Publication number: 20180273908
    Abstract: Disclosed are compositions and methods for increasing influenza virus production.
    Type: Application
    Filed: July 6, 2016
    Publication date: September 27, 2018
    Inventors: Ralph A. Tripp, Stephen M. Tompkins
  • Publication number: 20170369556
    Abstract: Disclosed are compositions and methods related to recombinant cells expressing microRNA and an immunoglobulin gene.
    Type: Application
    Filed: December 22, 2015
    Publication date: December 28, 2017
    Inventors: Ralph A. Tripp, Wu Weilin
  • Publication number: 20170151322
    Abstract: Provided herein are engineered cell lines. In some embodiments, cells of an engineered cell line have altered expression of a gene and/or altered expression of an miRNA, wherein the altered expression results in increased or decreased production of a virus. The virus is a picomavirus, such as a poliovirus or Enterovirus 71. Also provided herein are methods for using the engineered cells to produce virus, and methods for treating a subject having or at risk of having a viral infection.
    Type: Application
    Filed: February 5, 2014
    Publication date: June 1, 2017
    Inventors: Jon Michael Karpilow, Mark Steven Oberste, Ralph A. Tripp, Stephen M. Tompkins
  • Publication number: 20150374812
    Abstract: Provided herein are engineered cell lines. In some embodiments, cells of an engineered cell line have altered expression of a gene and/or altered expression of an miRNA, wherein the altered expression results in increased or decreased production of a virus. The virus is a picomavirus, such as a poliovirus or Enterovirus 71. Also provided herein are methods for using the engineered cells to produce virus, and methods for treating a subject having or at risk of having a viral infection.
    Type: Application
    Filed: February 5, 2014
    Publication date: December 31, 2015
    Inventors: Jon Michael Karpilow, Mark Steven Oberste, Ralph A. Tripp, Stephen M. Tompkins
  • Patent number: 8846056
    Abstract: Immunogenic polypeptides corresponding to one or more RSV G glycoproteins, or analogues thereof, are provided as components of vaccines. The inventive compositions are useful as both a prophylactic and therapeutic for the prevention and treatment of RSV infections and associated pulmonary or other diseases. The inventive immunogens include regions of the RSV G protein, specifically, amino acid residues 164-176 of RSV G A2 protein or analogues thereof. This inventive immunogen is operable alone or in combination with other polypeptides such as the RSV G protein amino acid residues 155-206, or other vaccines such as live RSV vaccines, or inactivated RSV vaccines or immunogenic analogues thereof.
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: September 30, 2014
    Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control
    Inventors: Larry J. Anderson, Lia M. Haynes, Ralph A. Tripp
  • Publication number: 20140288267
    Abstract: Compositions and methods are provided for the treatment or prevention of RSV disease by modulating RSV infection and immunity. In particular, amino acid sequences in the RSV G glycoprotein, containing the chemokine motif defined as C-X-X-X-C (or CX3C), are identified that are essential in causing RSV infection and disease. The chemokine motif is biologically active and participates in virus binding to and infection of susceptible cells. The prevention or treatment of RSV infection is achieved by interfering with the motif, such as by administering a vaccine in which the motif is altered or by administration or induction of blocking molecules that inhibit the biological activity of the motif.
    Type: Application
    Filed: April 15, 2014
    Publication date: September 25, 2014
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Service
    Inventors: Ralph A. Tripp, Les Jones, Larry J. Anderson
  • Patent number: 8778354
    Abstract: Compositions and methods are provided for the treatment or prevention of RSV disease by modulating RSV infection and immunity. In particular, amino acid sequences in the RSV G glycoprotein, containing the chemokine motif defined as C-X-X-X-C (or CX3C), are identified that are essential in causing RSV infection and disease. The chemokine motif is biologically active and participates in virus binding to and infection of susceptible cells. The prevention or treatment of RSV infection is achieved by interfering with the motif, such as by administering a vaccine in which the motif is altered or by administration or induction of blocking molecules that inhibit the biological activity of the motif.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: July 15, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Ralph A. Tripp, Les Jones, Larry J. Anderson
  • Patent number: 8771706
    Abstract: Immunogenic polypeptides corresponding to one or more RSV G glycoproteins, or analogs thereof, are provided as components of vaccines. The inventive compositions are useful as both a prophylactic and therapeutic for the prevention and treatment of RSV infections and associated pulmonary or other diseases. The inventive immunogens include regions of the RSV G protein, specifically, amino acid residues 164-176 of RSV G A2 protein or analogs thereof. This inventive immunogen is operable alone or in combination with other polypeptides such as the RSV G protein amino acid residues 155-206, or other vaccines such as live RSV vaccines, or inactivated RSV vaccines or immunogenic analogs thereof.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: July 8, 2014
    Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services
    Inventors: Larry J. Anderson, Lia M. Haynes, Ralph A. Tripp
  • Publication number: 20140121237
    Abstract: The present invention provides methods for treating a subject having, or at risk of having, a viral infection. The methods include, but are not limited to, the use of 4-(dipropylsulfamoyl)benzoic acid, an inhibitor of CDC25B phosphatase, an inhibitor of ICAM-1, an inhibitor of CamK2B, or a combination thereof.
    Type: Application
    Filed: October 14, 2013
    Publication date: May 1, 2014
    Inventors: RALPH A. TRIPP, STEPHEN M. TOMPKINS
  • Patent number: 8354115
    Abstract: The present invention provides methods and adjuvants for enhancing an immune response to RSV in a host, wherein the methods and adjuvants comprise a source of a CD40 binding protein. Preferably, the CD40 binding protein is CD40L and the source is a vector comprising a promoter operatively linked to a CD40L coding region. The enhanced immune response produced by the adjuvants and methods of the current invention includes both increased expression of Th1 cytokines and increased production of antibody.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: January 15, 2013
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Ralph A. Tripp, Larry J. Anderson, Michael P. Brown
  • Publication number: 20120258111
    Abstract: Compositions and methods are provided for the treatment or prevention of RSV disease by modulating RSV infection and immunity. In particular, amino acid sequences in the RSV G glycoprotein, containing the chemokine motif defined as C-X-X-X-C (or CX3C), are identified that are essential in causing RSV infection and disease. The chemokine motif is biologically active and participates in virus binding to and infection of susceptible cells. The prevention or treatment of RSV infection is achieved by interfering with the motif, such as by administering a vaccine in which the motif is altered or by administration or induction of blocking molecules that inhibit the biological activity of the motif.
    Type: Application
    Filed: January 25, 2012
    Publication date: October 11, 2012
    Applicants: Services
    Inventors: Ralph A. Tripp, Les Jones, Larry J. Anderson
  • Publication number: 20120148666
    Abstract: Immunogenic polypeptides corresponding to one or more RSV G glycoproteins, or analogues thereof, are provided as components of vaccines. The inventive compositions are useful as both a prophylactic and therapeutic for the prevention and treatment of RSV infections and associated pulmonary or other diseases. The inventive immunogens include regions of the RSV G protein, specifically, amino acid residues 164-176 of RSV G A2 protein or analogues thereof. This inventive immunogen is operable alone or in combination with other polypeptides such as the RSV G protein amino acid residues 155-206, or other vaccines such as live RSV vaccines, or inactivated RSV vaccines or immunogenic analogues thereof.
    Type: Application
    Filed: August 4, 2010
    Publication date: June 14, 2012
    Applicant: The Government of the USA, as Represented by the Secretary, Dept. of Health and Human Services, CDC
    Inventors: Larry J. Anderson, Lia M. Haynes, Ralph A. Tripp
  • Patent number: 8173131
    Abstract: Compositions and methods are provided for the treatment or prevention of RSV disease by modulating RSV infection and immunity. In particular, amino acid sequences in the RSV G glycoprotein, containing the chemokine motif defined as C-X-X-X-C (or CX3C), are identified that are essential in causing RSV infection and disease. The chemokine motif is biologically active and participates in virus binding to and infection of susceptible cells. The prevention or treatment of RSV infection is achieved by interfering with the motif, such as by administering a vaccine in which the motif is altered or by administration or induction of blocking molecules that inhibit the biological activity of the motif.
    Type: Grant
    Filed: May 26, 2005
    Date of Patent: May 8, 2012
    Assignee: PerkinElmer Health Sciences, Inc.
    Inventors: Ralph A. Tripp, Les Jones, Larry J. Anderson